← Back to Search

MED-Go App for Sickle Cell Disease

N/A
Recruiting
Led By Sherif M. Badawy, MD, MS
Research Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 12-21 years old
Any sickle cell disease genotype
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new app to help people with sickle cell disease take their medication as prescribed. The goal is to improve health outcomes for these patients.

Who is the study for?
This trial is for adolescents and young adults aged 12-21 with any type of sickle cell disease who have been on hydroxyurea steadily for at least 2 months. Participants must own or have access to a smartphone. Those recently hospitalized within the past week cannot join.
What is being tested?
The MED-Go app, a behavioral intervention designed to help young people with sickle cell disease take their medication regularly, is being tested for its ease of use and whether it's well-received by users in this pilot randomized controlled trial.
What are the potential side effects?
Since the intervention involves using an app (MED-Go) aimed at improving medication adherence, there are no direct medical side effects associated with it. However, participants may experience issues related to technology use such as eye strain or stress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 12 and 21 years old.
Select...
I have a type of sickle cell disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of patients achieving feasibility criteria of using the MED-Go app
Secondary study objectives
Hydroxyurea adherence rates
Scores of System Usability Scale (SUS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MED-Go app InterventionExperimental Treatment1 Intervention
Participants will use MED-Go app intervention for a total of 12 weeks
Group II: Control ArmActive Control1 Intervention
Standard of care

Find a Location

Who is running the clinical trial?

Ann & Robert H Lurie Children's Hospital of ChicagoLead Sponsor
273 Previous Clinical Trials
5,185,533 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,797,859 Total Patients Enrolled
Sherif M. Badawy, MD, MSPrincipal InvestigatorAnn & Robert H Lurie Children's Hospital of Chicago
2 Previous Clinical Trials
101 Total Patients Enrolled

Media Library

MED-Go App Clinical Trial Eligibility Overview. Trial Name: NCT04688411 — N/A
Sickle Cell Disease Research Study Groups: Control Arm, MED-Go app Intervention
Sickle Cell Disease Clinical Trial 2023: MED-Go App Highlights & Side Effects. Trial Name: NCT04688411 — N/A
MED-Go App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04688411 — N/A
~1 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top